Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Submucosal Cryotherapy With or Without Different Anti-inflammatory Drugs on Postoperative Pain and Interleukin-6 Levels in Maxillary Molars With Symptomatic Irreversible Pulpitis: A Randomized Clinical Study

NCT07919938 is registered in ClinicalTrials.gov with Suez Canal University as lead sponsor.

NCT NCT07919938 Not yet recruiting Phase 3 90 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07919938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, Phase 3, 90 participants (estimated). Lead sponsor Suez Canal University; Egypt. Primary measure: Postoperative Pain Intensity Assessed Using the Numeric Rating Scale (NRS).

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Submucosal Cryotherapy With or Without Different Anti-inflammatory Drugs on Postoperative Pain and Interleukin-6 Levels in Maxillary Molars With Symptomatic Irreversible Pulpitis: A Randomized Clinical Study
Lead sponsor
Suez Canal University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
November 15, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
21 Years
Maximum age
50 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
Egypt
Lead sponsor
Suez Canal University

Arms

As registered; 6 arms.

Registered arms
Arm Type Interventions
Anesthesia Alone (Control Group) Active comparator Articaine Hydrochloride With Epinephrine
Show registry wording

Participants will receive local anesthesia using one carpule of 4% articaine hydrochloride with epinephrine 1:100,000 administered by buccal infiltration, with supplemental palatal infiltration if needed. Standardized single-visit root canal treatment will be performed without additional submucosal cryotherapy or anti-inflammatory drug injections.

Submucosal Cryotherapy With Anesthesia Experimental Articaine Hydrochloride With Epinephrine, Submucosal Cryotherapy
Show registry wording

Participants will receive standard local anesthesia followed by a single submucosal injection of 1 mL cold normal saline (2-5°C) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment.

Diclofenac Sodium With Anesthesia Experimental Articaine Hydrochloride With Epinephrine, Diclofenac Sodium
Show registry wording

Participants will receive standard local anesthesia followed by a single submucosal injection of 1 mL diclofenac sodium (25 mg/mL; total dose 25 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment.

Dexamethasone With Anesthesia Experimental Articaine Hydrochloride With Epinephrine, Dexamethasone Sodium Phosphate
Show registry wording

Participants will receive standard local anesthesia followed by a single submucosal injection of 1 mL dexamethasone sodium phosphate (4 mg/mL; total dose 4 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment.

Submucosal Cryotherapy With Diclofenac Sodium Experimental Articaine Hydrochloride With Epinephrine, Diclofenac Sodium, Submucosal Cryotherapy
Show registry wording

Participants will receive standard local anesthesia followed by submucosal administration of cold normal saline (1 mL at 2-5°C) and diclofenac sodium (1 mL at 25 mg/mL) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. The interventions will be administered separately or sequentially according to the finalized study protocol.

+1 more arm

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Postoperative Pain Intensity Assessed Using the Numeric Rating Scale (NRS) At 6, 12, 24, 48, and 72 hours after root canal treatment.
Show registry wording

Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Participants will record their pain intensity at predefined postoperative intervals, and NRS scores will be compared among the six study groups.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • DEXAMETHASONE 12 Orange Book patentsPatent cliff April 26, 2041 (Orange Book patent)
    • US 12144889; expires April 26, 2041; assignee Ocular Therapeutix, Inc
    • US 11097061; expires June 23, 2039; assignee ICON Bioscience Inc
    • US 10537585; expires December 18, 2037; assignee Dexcel Pharma Technologies Ltd.
    • US 11304961; expires December 18, 2037; assignee Dexcel Pharma Technologies Ltd.
    • US 11458041; expires November 16, 2037; assignee Ocular Therapeutix, Inc
    • +7 more patents
  • Diclofenac 42 Orange Book patentsPatent cliff December 8, 2040 (Orange Book patent)
    • US 11707443; expires December 8, 2040; assignee RK Pharma Inc.
    • US 11850224; expires August 10, 2038; assignee RK Pharma Inc.
    • US 11110073; expires March 23, 2038; assignee Zydus Lifesciences Limited (India)
    • US 8546450; expires August 9, 2030; assignee Nuvo Research Inc.
    • US 8679544; expires April 23, 2030; assignee iCeutica (United States)
    • +37 more patents

Lead sponsor's other trials

Suez Canal University, most recent start first.

Similar trials

Same condition (Pulpitis) and phase, most recent start first.